THE Customer Excellence AGENCY

The GLP-1 Masterclass

in Customer Consciousness.

What the Most Consequential Category Event in a Generation Teaches Us About Commercial Strategy, Resource Allocation, and Unlocking the Next Generation of Growth.

Wayne Simmons, CCXP

Founder and Commercial Systems Architect

EXECUTIVE SUMMARY · CEA PRACTICE PAPER NO. 3 · JULY 2026

GLP-1 Is A Masterclass

In Customer Consciousness.

The dominant conversation in pharma boardrooms and C-suites right now is how do we get into the GLP-1 market?

That is the right question to ask.
It is not, however, the more interesting one.

The more interesting question is what comes after GLP-1.

The category formed where context was already present.

EXECUTIVE SUMMARY

The Argument in Brief

GLP-1 is one of the most powerful forces to move pharma, healthcare markets, and broader society in a generation. It is reshaping valuations, restructuring employer benefits, intensifying payer debates, redefining what primary care conversations look like, and changing what millions of people believe is possible for their own health and their own bodies.

The more interesting question is not which mechanism follows semaglutide or tirzepatide in the obesity pipeline. It is which human conditions are accumulating the same forces that made GLP-1 inevitable: persistent burden, normalized underservice, emotional intensity, cultural readiness, scientific unlock, and a deep demand for agency over a life condition that has felt intractable. That question is worth more than any single category entry, and it is the question that customer consciousness is built to answer.

The full Practice Paper argues that GLP-1 is more than a category story. It is a customer consciousness masterclass. Every condition that made it inevitable, every force that accelerated its adoption, and every dynamic now intensifying competition within it contains a lesson that customer-conscious companies can extract, systematize, and apply forward. The companies that do that work will not be chasing the next GLP-1. They will be creating it.

> ***Massive markets in pharma do not have to be bolts of lightning. Categories have an anatomy, the anatomy can be scored, and a scored anatomy can be run on a cadence against an entire portfolio.***

Two companies read it. That is the proof.

The word masterclass is chosen precisely, because a masterclass is taught by someone who did the thing well. Novo Nordisk and Eli Lilly both read the human context of obesity correctly, and both built the clinical credibility, prescribing confidence, and commercial architecture that turned an intervention into a category. None of the underlying evidence was hidden. The prevalence was documented, the failed interventions catalogued, the workaround spending visible on every retail shelf, and the cultural reframing of obesity from moral failure to metabolic condition underway in public for years. The reading was available to anyone looking, and two companies looked.

What follows from that demonstration is the harder observation, and it is not an indictment of anyone. Reading one condition correctly proves the reading is possible. It does not make it repeatable. In the commercial organizations I have worked inside and audited, no function has carried the remit of reading customer context ahead of category formation: no standing brief to detect human conditions accumulating toward a market, no cadence on which that detection runs, and no instrument carrying its

output into portfolio strategy. Reading one condition well produces a franchise. Reading any condition well produces a capability.

The consequence shows up in how the industry explains its own largest events. Category formation gets treated as weather. Something arrives, the science aligns with the moment, and a market appears where none existed. That account survives because it excuses everyone who missed it. The forces that produced obesity were present, legible, and enumerable years before the unlock, and equivalent forces are present, legible, and enumerable in other conditions today.

Six Findings

1	**GLP-1 did not create a customer need. It unlocked one that had been building for decades, and the companies that read it won.** *Persistent burden, normalized by clinical underservice and cultural stigma, created latent demand the science released instead of generating. The category was inevitable. Most strategy treated it as surprising.*
2	**The need was never weight loss. It was agency, and customers seeking agency behave as consumers.** *Patients self-recognized, self-funded, formed communities, and bypassed clinical infrastructure. High-agency conditions are consumer-grade markets and demand consumer-grade commercial architecture.*
3	**Category formation is not weather. It has an anatomy, and an anatomy can be instrumented.** *Two companies proved the read was available. Neither the industry nor its commercial model turned that into a standing capability, which is why the next convergence will be found by whoever happens to be looking closely at the right condition.*
4	**Seven conditions determine whether a human condition is approaching category formation.** *Persistent unresolved need, normalized burden, emotional and identity intensity, cultural readiness, patient self-recognition, scientific or technological unlock, and ecosystem expansion potential. Nine conditions already show strong convergence.*
5	**A supercycle is not demand creation. It is context debt discharging, and consumers have already paid the interest.** *Context debt is what an organization owes for burden it has heard and never acted on. It is visible in behavior long before it is visible in a market model: self-blame in how patients describe themselves, protocol-sharing in communities, cash-pay urgency, and the quiet exit from the clinical conversation.*
6	**Experience architecture is now the primary source of defensible advantage, and Customer Excellence is the Fourth Pillar that builds it.** *Launch, marketing, and sales excellence each optimize within categories that already exist. The Fourth Pillar reads the contexts that create them and governs whether value is realized inside them.*

Where the Pattern Is Already Forming

The conditions that made GLP-1 inevitable are not unique to obesity. The full Practice Paper assesses nine human conditions against the seven-condition model and plots each one on a strategic output grid. Five are then worked in depth, chosen because each illustrates a structurally different shape the pattern takes.

Longevity and Healthspan	**Women's Hormonal Health**	**Chronic Pain and Mobility**
Fertility and Reproductive Agency	**Mental Health and Performance**	**Sleep and Nervous System**
Metabolic Nutrition	**Cognitive Health and Focus**	**Caregiving Infrastructure**

In every one of these, consumers are already spending on solutions that do not meet the standard of scientific and regulatory rigor. The global wellness market exceeds two trillion dollars. Dietary supplements alone exceeded $180 billion in 2023. Compounded and bioidentical hormone therapy represents billions in annual spend directed at conditions the clinical system has chronically underserved. That spending does not forecast a market. It receipts a burden that was heard and never internalized.

> ***The workaround economy is not a sign of market immaturity. It is the most powerful demand signal available and the most honest audit of unread customer context in existence.***

What the Full Practice Paper Contains

This summary sets out the argument. The Practice Paper sets out the method, and it is written so that a commercial leader can run it against their own portfolio using nothing beyond the document.

In the Full Paper	What It Gives You
The Convergence Readiness Model™	The seven conditions defined in full, with the GLP-1 read on each, and a two-axis output grid that converts a diagnostic reading into a strategic position. Applicable to any therapeutic adjacency or investment opportunity under consideration.
The Replication Protocol	Five practices in sequence that convert lived human experience into a category thesis, with the reasoning for why the order matters and what each practice surfaces that conventional research does not.
A worked replication	The protocol run end to end on a single condition, so the technique is demonstrated and not merely described. This is the section that shows what a design brief looks like when it is written before the asset exists.
The nine-condition assessment	All nine conditions scored across the seven dimensions and plotted, with five worked in depth and a directional Customer Excellence implication for each.
An allocation logic	A method for converting a diagnostic read into a capital decision, with a defined posture, instrument set, capital profile, and return mechanism for each position on the output grid.
The Fourth Pillar argument	The structural case for Customer Excellence alongside launch, marketing, and sales excellence, and what it owns upstream in portfolio, midstream in architecture, and downstream in value realization.

ABOUT THE PRACTICE

The Customer Excellence Agency helps global pharmaceutical companies build the **predisposition to unlock customer and experience-led growth**: the standing capacity to read customer context before a market forms, to architect consumer-grade commercial systems around what that reading finds, and to govern whether the value the science promises is actually realized in a customer's life.

Wayne Simmons, CCXP, is Founder and Commercial Systems Architect of CEA, author of *The Customer Excellence Enterprise* (Wiley), founding faculty in the MS in Customer Experience Management at Michigan State University's Broad College of Business, and a former senior commercial and CX leader at Pfizer and Bayer.

Request the full Practice Paper at cxedna.com